

MPM CORPÓREOS S.A.
Publicly-Held Company with Authorized Capital
Brazilian Taxpayers Registry No. 26.659.061/0001-59
NIRE: 35.300.498.607

NOTICE TO SHAREHOLDERS

ANNEX E TO CVM RESOLUTION No. 80

Communication on capital increase resolved by the Board of Directors

MPM CORPÓREOS S.A. ("Company") pursuant to the provisions of "Annex E" of CVM Resolution No. 80, dated March 29, 2022, hereby presents additional information to the Material Fact disclosed on this date ("Material Fact") about the Company's capital increase within the authorized capital limit, pursuant to Article 6 of the Company's bylaws ("Capital Increase"), approved at a Board of Directors' meeting held on this date:

(Except as specifically defined in this Notice to Shareholders, capitalized terms not defined herein have the meaning attributed in the Material Fact)

1) The issuer must disclose to the market the amount of the increase and the new capital share, and whether the capital increase will be made through: (a) conversion of debentures or other debt security into shares; (b) exercise of subscription right or subscription bonus; (c) capitalization of profits or reserves; or (d) subscription of new shares.

The Capital Increase will be a minimum of BRL 85,000,001.28 ("Minimum Amount") and a maximum of BRL 225,000,000.00 ("Maximum Amount"), upon the issuance by the Company of a minimum of 44,270,834 new common shares and a maximum of 117,187,500 new common shares, nominative, book-entry and with no par value ("New Shares"), at price of BRL 1.92 per share. Partial subscription of the New Shares and the consequent partial homologation of the Capital Increase will be allowed, as long as it reaches at least the Minimum Amount, observing the shareholders' right to the prerogative granted by article 31 of CVM Instruction No. 400, of December 29, 2003, as amended, according to the procedures foreseen in item 4.(xvi) below.

Thus, considering item 4.(v) below, which provides that part of the price per share will be allocated to the formation of the capital reserve, the Company's share capital could increase from the current BRL 1,303,361,932.19 divided into 244,235,566 common shares, nominative, book-entry and with no par value, (i) assuming the homologation of the Capital Increase at the Minimum Amount, to BRL 1,371,539,016.55 divided into 288,506,400 common shares, nominative, book-entry and with no par value; and (ii) assuming the homologation of the Capital Increase at the Maximum Amount, to BRL 1,483,830,682.19 divided into 361,423,066 common shares, nominative, book-entry and with no par value.

2) The issuer shall explain in detail the use of proceeds of the Capital Increase and its legal and economic consequences:

The Capital Increase is intended to strengthen the capital structure, improve the cash position and reduce the Company's consolidated financial leverage.

The Capital Increase may lead to corporate dilution of the interest of the Company's current shareholders that do not exercise their preemptive rights to subscribe the Shares, as foreseen in subitems (vii) and (xiii) of item 4 below.

Except for the above, the Company's Board of Directors does not foresee any legal or economic consequences other than those normally expected in a capital increase by private subscription.

3) The issuer shall provide a copy of the opinion of fiscal council, as applicable

The minutes of the meeting containing the opinion of the fiscal council are available on the Company's website <https://ri.espacolaser.com.br/en/>. On this page "CVM Filings", click on "Minutes and Meetings of the Assembly" then select "FCM – 08.25.2022".

4) In case of Capital Increase upon subscription of shares, the issuer must:

(i) Describe the use of proceeds:

The Capital Increase is intended to strengthen the capital structure, improve the cash position and reduce the Company's consolidated financial leverage.

(ii) Inform the number of issued shares of each type and class:

Shall be issued a minimum of 44,270,834 New Shares and a maximum of 117,187,500 New Shares subject to the provisions of item 4.(xvii) below.

(iii) Describe the rights, advantages and restrictions attributed to the shares to be issued:

The New Shares to be issued will be entitled to equal rights with those already existing, including full participation in any distributions of dividends, interest on equity and capital remuneration that may be declared by the Company after the date of publication of the minutes of the Company's Board of Directors meeting that approves the homologation of the Capital Increase.

(iv) Inform whether the related parties, as defined by the accounting rules dealing with this matter, will subscribe shares in the Capital Increase, specifying the respective amounts when this amounts are already known:

The shareholders Ygor Alessandro de Moura, Paulo José Iász de Moraes, SMZXP Participações Ltda., Mafalda Hungria Bayam Veiga Pinto and Magnólia Fundo de Investimento ("Relevant Shareholders") (in Portuguese, Acionistas de Referência) have committed to exercise, directly and/or indirectly (with the right to assign their preemption rights among each other), all their respective preemptive rights for the subscription of New Shares. The Relevant Shareholders will exercise their preemptive rights on an amount equivalent to approximately 39.6% of the Company's capital share, which also considers the assignment of all preemptive rights held by Tito Virgílio Augusto Veiga Pinto and Maria Lucia Ataíde Martins to the Relevant Shareholders. Additionally, the Relevant Shareholders may at their own discretion participate in the subscription of remaining shares

(v) Inform the price per share of the new shares:

The price of the New Shares will be R\$1.92 per share. Further details on the calculation criteria of the price are described in item 4 (viii) below.

(vi) Inform the par value of the issued shares or, in the case of shares without par value, the portion of the price that will be allocated to the capital reserve:

The New Shares have no par value.

Of the price per share, (i) BRL 1,54 will be allocated to the share capital, total amounting up to BRL 180,468,750.00, assuming subscription of the maximum number of New Shares; and (ii) the remaining amount of BRL 0.38 per share will be allocated to the formation of a capital reserve, pursuant to article 182, paragraph 1, 'a', of the Brazilian Corporate Law, total amounting up to BRL

44,531,250.00, assuming subscription of the maximum number of New Shares.

(vii) Provide management's Opinion on the effects of the Capital Increase, especially regarding the dilution caused by the increase:

As set forth in item 2 above, the Company's management believes that, under the proposed terms and conditions, the Capital Increase creates value for shareholders to the extent it seeks to optimize the Company's capital structure.

Considering that the preemptive rights will be ensured to the Company's shareholders, pursuant to article 171 of the Brazilian Corporate Law, there will be no corporate dilution of shareholders who subscribe the new Shares in proportion to their respective stakes in the Company's capital share. Only the Company's shareholder that does not exercising its preemptive right or for exercising it partially will have its participation diluted.

Finally, the management believes that the issue price of the Shares was established so as not to cause unjustified economic dilution for the Company's current shareholders, as explained in the following item.

(viii) Inform the criterion of the calculation of the issue price and justify in detail the economic aspects that determined its choice:

The price of BRL 1.92 per share was fixed without unjustified dilution of the Company's current shareholders, pursuant to article 170, paragraph 1, III, of Brazilian Corporate Law, considering the closing price of the Company's shares on B3 S.A. – Brasil, Bolsa, Balcão ("B3") on August 30, 2022, with a 20% discount.

The Board of Directors' members believe that (i) the share pricing criteria adequately reflects the current market value of the Company's shares; and (ii) the discount was established at a level compatible with market practices, based on similar transactions carried out in recent years.

(ix) If the price per share was set with premium or discount in relation to the market value, identify the reason for the premium or discount and explain how it was determined:

A discount of 20% was applied in order to stimulate the Company's minority shareholders to participate in the Capital Increase.

(x) Provide a copy of all valuation reports and studies that based the fixed price per share:

No evaluation report was issued to support the establishing of the price per share.

(xi) Inform the price of each type and classes of shares of the Company in the markets in which they are traded, identifying:

(a) minimum, average and maximum price of each year, in the last three (3) years:

BRL	2021	2020	2019
Minimum	7.70	-	-
Average	15.70	-	-
Maximum	21.67	-	-

(b) minimum, average and maximum price of each three-month period, in the last two (2)

years:

BRL	3Q19	4Q19	1Q21	2Q21	3Q21	4Q21	1Q22	2Q22
Minimum	-	-	15.60	14.98	14.99	7.70	3.67	2.11
Average	-	-	18.48	17.18	18.18	9.97	5.43	3.79
Maximum	-	-	21.67	19.70	21.26	15.34	8.32	6.18

(c) minimum, average and maximum price of each month, in the last six (6) months:

BRL	Feb/22	Mar/22	Apr/22	May/22	Jun/22	Jul/22
Minimum	4.32	3.67	4.18	3.09	2.11	2.18
Average	5.21	4.52	5.25	3.52	2.60	2.59
Maximum	6.47	5.90	6.18	4.30	2.98	2.98

(d) Average price in the last 90 (ninety) days:

The average price of the Company's shares in the last 90 (ninety) days was BRL 2,63.

(xii) Inform the price per share of shares in capital increases made in the last three (3) years:

Capital Increase Date	Price of Shares (BLR)
02/19/2021	2.94
02/19/2021	10.92
01/28/2021	17.90
11/11/2019*	-

*It should be clarified that the capital increase approved by the Company's Board of Directors on November 11, 2019 was carried out through the conversion of profit reserves, without modifying the number of shares, in accordance with article 169, paragraph 1 of the Brazilian Corporate Law

(xiii) Present the percentage of potential dilution resulting from the Capital Increase:

Shareholders that do not subscribe any shares during the period for exercise of preemptive rights in the context of the Capital Increase will have their respective interest in the Company diluted by a minimum of 15.34% and a maximum of 32.42%.

(xiv) Inform the terms, conditions and form of subscription and payment of the shares issued:

(a) Term for exercising the preemptive rights:

The preemptive right must be exercised during the period from September 5, 2022 (including) to October 4, 2022 (including), being that: (i) for shareholders that do it through a custody agent (broker) in the B3 Depository environment, the period will expire on October 3, 2022, at 8:00p.m.; and (ii) for shareholders that do it through the Bookkeeping Agent, the period will expire on October 4, 2022, at 4:00p.m.

Shares acquired as of September 5, 2022 (including) will not be eligible for preemptive rights by the acquiring shareholder, and will be traded ex-subscription rights.

(b) Payment conditions and procedure:

The Shares shall be paid in a single installment, in national currency at the time of subscription, in compliance with the rules and procedures of the B3 Depository and the Bookkeeping Agent, being that (i) if the preemptive right is exercised through a custody agent (broker) within the B3 Depository, such agent will receive the amounts referring to the subscription of the New Shares from the account of the subscribing shareholders until October 5, 2022, subject to any deadlines, procedures and operating rules of each custody agent; and (ii) if the preemptive right is exercised through the Bookkeeping Agent, the payment for the subscriptions exercised shall be made by the subscriber at the time of subscription.

The same payment procedure will be applied to the subscribed Shares in the apportionment of the remaining shares, to be disclosed through a Notice to Shareholders as described in item 4.(xvi) below.

(c) Subscription procedure:

Holders of preemptive rights held in custody at the B3 Depository that wish to exercise their preemptive rights must do so through their custody agents (brokers) and pursuant to the B3 Depository rules.

Considering the operational procedures adopted by each custody agent (broker), it is recommended that shareholders that wish to participate in the Capital Increase contact the custody agent before exercising their preemptive rights, in order to: (i) verify the need to maintain funds in an opened account and/or maintained therein, for purposes of guaranteeing their respective preemptive rights; (ii) verify the possibility of early debit of the account by the custody agent (broker); (iii) obtain detailed information on the deadlines established for the realization of the preemptive right, subject to the operational procedures adopted by each custody agent; and (iv) update and/or make the registration with that custody agent.

The holders of preemptive rights held in custody at the Bookkeeping Agent that wish to exercise their respective preemptive rights shall within the preemptive right period described in item 4 above go to any branch of the Bookkeeping Agent in the national territory. On this occasion, the shareholders shall fill and sign a subscription form to be made available by the Bookkeeping Agent and deliver the documentation listed in sub-item (d) below.

The preemptive right shall be exercised by signing the subscription form, according to the model to be made available by the Bookkeeping Agent, and the delivery of the documentation listed in sub-item (d) below, which shall be presented by the shareholder (or preemptive right assignee) directly at a branch of the Bookkeeping Agent. The Bookkeeping Agent's investors service is available on Business Days, from 9am to 6pm, through the phones 3003 9285, for capitals and metropolitan regions, or 0800 720 9285, for the other regions.

(d) Documentation for the exercise or the assignment of subscription rights:

The holders of subscription rights held in custody at the B3 Depository that wish to exercise their respective preemptive rights or assign such rights shall consult their respective custody agents (brokers) regarding the necessary documentation, in compliance with the deadlines established by B3 and the conditions of this Notice to Shareholders.

The holders of preemptive rights held in custody in the Bookkeeping Agent that wish to exercise their respective preemptive rights or assign such rights through the Bookkeeping Agent shall present the following documents:

- Individual: (i) identity document (RG or RNE); (ii) supporting document of enrollment with the Individual Taxpayer Registry (CPF); and (iii) proof of residence;
- Legal Entity: (i) copy of the effective and consolidated bylaws, along with the minutes of the corporate act of election of the current statutory board or certified copy of the effective and consolidated bylaws, (ii) proof of enrollment with the National Register of Legal Entities (CNPJ), (iii) certified copy of the corporate documents that prove the powers of the signatory of the subscription form, and (iv) certified copy of the identity document, proof of enrollment in the Individual Taxpayer Registry (CPF) and proof of residence of the signatory(ies). Additional documents may be required from investors residing abroad;
- Investment Fund: (i) copy of the current and consolidated regulations of the investment fund, bylaws or current and consolidated social contract of its portfolio manager or its administrator, as the case may be, observing the voting policy of the investment fund and corporate documents that prove the powers of representation (minutes of election of directors, instrument(s) of appointment and/or power of attorney); (ii) proof of enrollment with the National Register of Legal Entities (CNPJ), (iii) certified copy of the corporate documents that prove the powers of the signatory of the subscription form, and (iv) certified copy of the identity document, proof of enrollment with the Individual Taxpayer Registry (CPF), and proof of residence of the signatory(ies); and
- Representation by Power of Attorney: in this case, it will be necessary to present a public power of attorney with specific powers, accompanied by the documents mentioned above, as applicable, of the grantor and the attorney-in-fact. Foreign investors may be required to present other representation documents, under the terms of the applicable legislation.

(xv) To inform if the shareholders shall have preemptive rights to subscribe the new shares issued and detail the terms and conditions to which this right is subject:

Subject to the procedures established by Itaú Corretora de Valores S.A., the bookkeeping agent for the shares issued by the Company ("Bookkeeping Agent") and by B3's Central Depository ("B3 Depository"), the shareholders will have the right to exercise their preemptive right in the subscription of 0.4798134110 New Share for each Company's share that they hold at the closing of B3's trading session on September 2, 2022, assuming the approval of the Capital Increase by the maximum number of New Shares. Fractions of shares resulting from the calculation of the percentage for the exercise of the preemptive right, as well as the right to subscribe to the remaining shares or apportionment of shares will be disregarded. Fractions of shares will subsequently be grouped into whole numbers of shares and will be object of apportionment of remaining shares and may be subscribed by shareholders who expressed interest in the remaining shares during the subscription period, as described in item 4.(xvi) below.

Negotiation and/or Assignment of the Preemptive Right . Preemptive rights in the subscription of the New Shares to be issued may be traded on a stock exchange or in a private trading environment, as well as may be freely assigned at the shareholders discretion, in whole or in part, pursuant to

article 171, paragraph 6 of the Brazilian Corporate Law. Thus, shareholders who wish to negotiate and/or assign their preemptive rights may do so during the period of the exercise of its preemptive rights, and they shall proceed in advance in order to allow the preemptive rights negotiated and/or assigned can be exercised within the period of the preemptive right.

Shareholders that hold shares issued by the Company registered in the records kept by the Bookkeeping Agent and that wish to privately assign their preemptive rights should request the Bookkeeping Agent to issue the respective rights assignment agreement, available at any branch of the Bookkeeping Agent in the national territory, by presenting the documentation listed above.

Shareholders whose shares are deposited at the B3 Depository and that wish to trade their preemptive rights must contact and instruct their respective custody agent (broker), in accordance with the rules established by the B3 Depository. Trading of preemptive rights at B3 will close on September 29, 2022.

For further details on deadlines, procedures and conditions see item 4.(xiv) and the Material Fact.

(xvi) Inform the management's proposal for the treatment of eventual remaining shares:

Once the period for the exercise of the preemptive rights has ended, the holders of preemptive rights must express their interest in reserving any remaining shares and additional remaining shares in their respective subscription forms.

Regarding the subscription period for remaining shares, the holders of preemptive rights that have expressed their interest in reserving remaining shares on the subscription form will have a period of five Business Days from the publication of the notice to shareholders that will inform the calculation of remaining shares to effectively subscribe the remaining shares, by completing and signing the subscription form and paying the price per share of the corresponding New Shares according to item 7 of the Material Fact. The remaining shares will be calculated again and then apportioned among the shareholders that have expressed their interest in reserving additional remaining shares on the subscription form.

If the total number of shares subject to requests for additional remaining shares exceeds the amount of remaining shares available in the apportionment of remaining shares, there will be a proportional apportionment among the subscribers who have requested additional remaining shares.

The percentage for the exercise of the subscription rights to remaining shares will be obtained by dividing the number of remaining New Shares by the total number of New Shares subscribed by preemptive rights' holders that have expressed an interest in remaining shares during the preemptive rights period, multiplying the quotient obtained by 100. The same logic will be applied to any additional remaining shares.

The specific procedures and deadlines for the subscription and payment of the remaining shares will be detailed eventually by the Company by means of a notice to shareholders.

Considering the possibility of the partial homologation of the capital increase if the Minimum Amount is reached, no auction of remaining shares will be held when the apportionment of remaining shares is concluded.

(xvii) Describe in detail the procedures that will be adopted in case of partial homologation of the capital increase:

Partial subscription and consequent partial homologation of the Capital Increase will be admitted.

Due to the possibility of partial homologation of the Capital Increase, holders of preemptive rights may, at the time they exercise their subscription rights:

- (iii) condition the subscription of the New Shares to the placement, in the Capital Increase, of all the New Shares at the Maximum Amount, provided that in the event the totality of the New Shares is not placed at the Maximum Amount the respective subscription form will be cancelled;
- (iv) if the placement of New Shares in the Capital Increase is equal to or greater than the Minimum Amount and less than the Maximum Amount, condition: (ii.a) subscription of all of the New Shares indicated on the subscription list; or (ii.b) subscription of an amount equivalent to the proportion between the number of New Shares actually placed in the Capital Increase and the maximum number of New Shares, if the Capital Increase were to be carried out at the Maximum Amount, applied to the number of New Shares indicated by the shareholder on the subscription form. If the holder of preemptive rights chooses to condition his subscription in the form of item "(ii.b)" above, the holder of preemptive rights must indicate, at the time of the subscription, his complete banking details, so that the Company may return the excess amount.

In the absence of express manifestation in the subscription form, the interest of the holder of the preemptive right in maintaining his subscription decision in full will be presumed. In any event, the shareholder's decision will be final and irreversible, and it will not be possible to change it afterwards. Since, during the period for exercising the preemptive right, the shareholders will have the possibility, when signing the subscription form, to condition their subscription to the aforementioned hypotheses, there will be no deadline for reviewing the investment, so that the shareholders will have to manifest their decision before the subscription.

In the event of partial subscription of the Capital Increase, the holder of preemptive rights that subjects its subscription pursuant to item "(ii. b)" above will receive, within two business days from the date of publication of the minutes of the meeting of the Company's Board of Directors that homologates the Capital Increase, the return of the amount paid without interest or monetary correction or reimbursement of costs incurred and with deduction, if applicable, of any taxes or fees (including, without limitation, any applicable taxes on financial transactions, the IOF/Exchange and any other taxes that may be created, as well as those whose rate currently equivalent to zero will be increased) eventually charged.

Subscription Receipt

- Subscription Receipts at the B3 Depository: The subscription receipts of New Shares subscribed under the exercise of preemptive rights at B3 will be available to the subscribers on the business day subsequent to the date of payment of the New Shares, as described in item 7 of the Material Fact. The subscription receipts for New Shares subscribed for in the context of the request for remaining shares at B3 will be available to subscribers on the date of publication of the notice to shareholders communicating the opening of the period and procedures for the subscription of remaining shares at the B3 Depository, as described in item 8 of the Material Fact.
- Subscription Receipts at the Bookkeeping Agent: Subscription receipts for shares subscribed under the exercise of preemptive rights at the Bookkeeping Agent will be available to the subscribers immediately upon signing the subscription form.

Subscription receipts cannot be negotiated by the subscribers who have conditioned their subscription in the manner described in sub-item "(ii)" of item 4.xvii above. Therefore, the Company will not be

responsible for any losses resulting from the negotiation of subscription receipts under such conditions, given that they are subject to future and eventual conditions.

Share Availability. The New Shares issued will be credited to their subscribers on the business day following the date of publication of the minutes of the Company's Board of Directors meeting that homologates the Capital Increase and should be viewable in the shareholders' statements as from the 3rd business day following the date of publication of the minutes of the Company's Board of Directors meeting that homologates of the Capital Increase.

(xviii) **In case the price per shares can be, totally or partially, paid in assets: (a) present a complete description of the assets that will be accepted; (b) clarify the relation between the assets and its corporate purpose; and (c) provide a copy of the valuation report of the assets, in case it is available.**

Not applicable.

Further information can be obtained from the Company's Investor Relations Department, through the e-mail address dri@espacolaser.com.br.

Leonardo Moreira Dias Correa
Chief Financial and Investor Relations Officer